TIL Therapy Entering the Mainstream
Mené sur 168 patients atteints d'un mélanome de stade avancé, cet essai multicentrique de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ipilimumab et d'un traitement utilisant des lymphocytes ayant infiltré la tumeur
Melanomas have long been considered to be immunogenic tumors. Although anti–programmed death 1 (PD-1) therapy has been approved worldwide as first-line treatment, many patients do not benefit from it, so there is an important therapeutic gap. Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) was described in the 1980s by Rosenberg and colleagues.1 This personalized treatment for cancer is based on the infusion of autologous T lymphocytes that have been obtained directly from surgically removed autologous tumors and then expanded in culture with the use of interleukin-2 stimulation. Both preconditioning lymphodepletion with high-dose, nonmyeloablative chemotherapy and the intravenous administration of high-dose (...)
New England Journal of Medicine , éditorial, 2021